Presently, there are numerous structural classes of cannabinoid receptor agonists, all of which require solubilization for experimental purposes. One strategy for solubilizing water-insoluble tetrahydrocannabinols is conversion of the phenolic hydroxyl to a morpholinobutyryloxy substituent. The hydrochloride salts of these analogs are water-soluble and active in vivo when administered in saline. The present investigation demonstrated that hydrochloride salts of numerous substituted butyryloxy esters are water-soluble and highly potent. The substitutions include piperidine, piperazine, and alkyl-substituted amino moieties. It was also discovered that incorporation of a nitrogenous moiety in the alkyl side chain increased the pharmacological potency of tetrahydrocannabinol. For example, an analog containing a pyrazole in the side chain (O-2545) was found to have high affinity and efficacy at cannabinoid 1 (CB 1 ) and CB 2 receptors, and when dissolved in saline, it was highly efficacious when administered either intravenously or intracerebroventricularly to mice. A series of carboxamido and carboxylic acid amide analogs exhibited high pharmacological potency, but their hydrochloride salts were not water-soluble. On the other hand, incorporation of imidazoles into the terminus of the side chain led to water-soluble hydrochloride salts that were highly potent when administered in saline to laboratory animals. It is now possible to conduct cannabinoid research with agonists that are water-soluble and thus obviating the need of solubilizing agents.
⌬ 9 -THC was administered a mixture of ethanol, Emulphor, and saline for systemic administration and in dimethyl sulfoxide for spinal injection because neither vehicle was suitable for both routes of administration (Lichtman and Martin, 1991) . In vitro studies present other problems in that many of the surfactants that are tolerated in vivo dissolve membranes, thereby destroying the cell preparation. Of course, all of these potential pitfalls are magnified with chronic drug administration or with long drug exposures in vitro. It is for these reasons that there have been numerous attempts to prepare water-soluble derivatives of cannabinoids.
The first successful attempt in preparing a water-soluble form of ⌬ 9 -THC involved converting it to a morpholinobutyryl ester, the hydrochloride of which was water-soluble (Zitko et al., 1972) . This compound retained cannabinoid pharmacological activity. A morpholinobutyryl ester of ⌬ 8 -THC was also found to be equipotent to ⌬ 8 -THC in several behavioral models (Compton and Martin, 1990) . Water-soluble derivatives of ⌬ 8 -THC were prepared in other laboratories and found to be effective in lowering intraocular pressure in rabbits (ElSohly et al., 1984) . In more recent times, numerous cannabinoid analogs have been developed that are considerably more potent than ⌬ 9 -THC (Martin et al., 1999; Khanolkar et al., 2000) . One of these compounds contains a cyano group on the terminal carbon atom of the side chain in ⌬ 8 -THC (Martin et al., 1999) . Therefore, a morpholinobutyryl ester of this potent cannabinoid was prepared and found to be highly active when prepared in saline and evaluated either in vivo or in vitro (Pertwee et al., 2000) . It is assumed that these phenolic esters (Zitko et al., 1972; Pertwee et al., 2000) are prodrugs because a free hydroxyl group is required for pharmacological activity of ⌬ 9 -THC at the CB 1 cannabinoid receptor (Razdan, 1986; Huffman et al., 2002) . Phosphate esters of the endocannabinoids anandamide and noladin ether have also been prepared (Juntunen et al., 2003a,b) . These esters are rapidly hydrolyzed in biological tissues and are effective in lowering intraocular pressure in rabbits when applied in an aqueous solution.
There have also been numerous attempts to prepare analogs with reduced lipophilicity. Early receptor binding studies conducted with radiolabeled ⌬ 8 -THC were of limited success because of the extensive nonspecific binding by this highly lipophilic agent (Harris et al., 1978) . In an effort to reduce nonspecific binding, Nye et al. (1988) prepared a radiolabeled trimethylammonium analog of ⌬ 8 -THC. This charged analog allowed them to label a specific binding site in brain, although it remains to be established that this site is a true cannabinoid receptor. A nitrogen mustard analog of ⌬ 9 -THC was found to be behaviorally active when administered centrally but not when administered peripherally, presumably because of its reduced lipophilicity (Little et al., 1987) . In addition to the ⌬ 9 -THC analogs cited above, numerous aminoalkylindole and biarylpyrazole cannabinoid analogs have been prepared that have reduced lipophilicity (Gatley et al., 1998; Kumar et al., 2004; Deng et al., 2005; Willis et al., 2005) . Many of these compounds were developed as possible positron emission tomography radiotracers. Some of these antagonists were prepared in saline and administered to animals, but only at tracer concentrations. It is unlikely that they can be administered in saline at sufficient levels to achieve a pharmacological response.
The present investigation was undertaken to further explore possible alterations in the ⌬ 8 -THC structure that would render it water-soluble. An additional objective was to develop a series of water-soluble analogs that were not prodrugs.
Materials and Methods

Materials.
Male Institute for Cancer Research mice (Harlan Laboratories, Indianapolis, IN) weighing between 24 to 30 g were used in all experiments. Mice were maintained on a 14-light/10-h dark cycle with food and water available ad libitum. All test groups consisted of six to 12 mice. ⌬ 9 -THC was obtained from National Institute on Drug Abuse (Bethesda, MD) and dissolved in a vehicle consisting of ethanol, Emulphor, and saline in a ratio of 1:1:18. Analogs were dissolved either in the vehicle or saline depending upon their water solubility. All chemicals for receptor binding studies were purchased from Sigma (St. Louis, MO), with the exception of the following chemicals. [ 35 S]GTP␥S (1250 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Wellesley, MA), GTP␥S was from Roche Diagnostics (Indianapolis, IN), Dulbecco's modified Eagle's medium (DMEM) was from Invitrogen (Carlsbad, CA), Whatman GF/B glass fiber filters were from Fischer Scientific (Pittsburg, PA), fetal calf serum and fetal bovine serum were from HyClone Laboratories (Logan, UT), and Budget-Solve scintillation fluid was from RPI Corp. (Mount Prospect, IL).
Membrane Preparations. Human embryonic kidney-293 cells stably expressing the human CB 1 receptor were cultured in DMEM with 10% fetal bovine serum, and Chinese hamster ovary cells stably expressing the human CB 2 receptor were cultured in DMEM with 10% fetal calf serum. Cells were harvested by replacement of the medium with ice-cold phosphate-buffered saline containing 1 mM EDTA followed by centrifugation at 1000g for 5 min at 4°C. The pellet was resuspended in 50 mM Tris-HCl containing 320 mM sucrose, 2 mM EDTA, and 5 mM MgCl 2 , pH 7.4 (centrifugation buffer), and then centrifuged at 1000g for 10 min at 4°C, and the resulting supernatant was saved. This process was repeated twice. The supernatant fractions were combined and centrifuged at 40,000g for 30 min at 4°C. The resulting P2 pellet was resuspended in assay buffer (50 mM Tris-HCl, pH 7.4, 3 mM MgCl 2 , 0.2 mM EGTA, and 100 mM NaCl), and protein was measured. Membranes were stored at Ϫ80°C until use.
Receptor Binding. Membrane homogenates (50 g) were incubated with 0.5 nM [ 3 H]CP 55,940 in the presence of varying concentrations (1 nM-10 -M) of test compounds in 0.5 ml of buffer containing bovine serum albumin (5 mg/ml). Nonspecific binding was measured in the presence of 1 M CP 55,940. The assay was incubated at 30°C for 1 h and terminated by the addition of ice-cold 50 mM Tris-HCl containing bovine serum albumin (1 mg/ml, pH 7.4) followed by filtration under vacuum through Whatman GF/B glass fiber filters with three washes with ice-cold Tris buffer. Bound radioactivity was determined by liquid scintillation spectrophotometry at 50% efficiency after extraction by shaking samples for 30 to 60 min with Budget-Solve scintillation fluid. Data are reported as the mean Ϯ S.E.M. of three experiments, each performed in triplicate. K i values were calculated from displacement data using Equilibrium Binding Data Analysis (BIOSOFT, Milltown, NJ).
[ 35 S]GTP␥S Binding Assays. Concentration-effect curves were generated by incubating membranes (10 g) in assay buffer ϩ bovine serum albumin (1 mg/ml) with various concentrations of test compounds in the presence of 20 M GDP and 0.1 nM [
35 S]GTP␥S in a 1 ml of total volume. [
35 S]GTP␥S binding stimulated by 2 M CP 55,940 was used as an internal standard in each assay. Basal binding was assessed in the absence of agonist, and nonspecific binding was measured in the presence of 10 M GTP␥S. The reaction was incubated for 90 min at 30°C and terminated by filtration under vacuum through Whatman GF/B glass fiber filters with three washes with ice-cold (4°C) Tris buffer (50 mM Tris-HCl, pH 7.4).
Water-Soluble Cannabinoids
Bound radioactivity was determined by liquid scintillation spectrophotometry at 95% efficiency after extraction overnight in ScintiSafe Econo 1 scintillation fluid (Fisher Scientific, Hampton, NH Behavioral Evaluations. All animals were allowed to acclimate to the observation room overnight. Behavioral effects were assessed in the tetrad model to measure potency in producing antinociception, catalepsy, hypothermia, and hypomobility. The baselines for tailflick latency (2-4 s) and rectal temperature were determined before i.v. injections. Baseline rectal temperatures were measured using a telethermometer and a thermometer probe inserted to 25 mm (Yellow Springs Instrument Co., Yellow Springs, OH). The mice treated i.v. with an analog were placed in individual photocell activity chambers 5 min later. Spontaneous activity was monitored for 10 min in a Digiscan Animal Activity Monitor (Omnitech Electronics, Inc., Columbus, OH) as measured by the number of interruptions of 16 photocell beams per chamber. The total number of beam interruptions during the 10-min period was determined and presented as total counts. The mice were then assessed at 20 min following the i.v. injection for antinociception using the tail-flick reaction time to a heat stimulus. A 10-s maximal latency was used to avoid tail injury. The results are presented as %MPE and are calculated as follows: %MPE ϭ [(test latency Ϫ control latency)/(10 s Ϫ control latency)] ϫ 100.
Rectal temperature was measured 30 min after the i.v. injection. The change in rectal temperature (⌬°C) following analog administration was calculated for each animal. Relative immobility (catalepsy) was measured 40 min after the i.v. injection by the ringimmobility test. Mice were placed on a ring 5.5 cm in diameter attached to a stand at a height of 16 cm. The amount of time the mice spent motionless on the ring during the 5-min procedure was measured, with the criteria of immobility defined as the absence of all voluntary movements, including whisker movement but excluding respiration. The percentage immobility was calculated as follows: % immobility ϭ [time immobile (s)]/[length of session (s)] ϫ 100. Mice that fell from the ring or actively jumped were allowed five attempts. After the fifth escape, these mice were removed from the ring and not included in the calculations. Data were collected from six to 12 mice for each condition tested.
A similar protocol was used to determine the effects of analogs after either i.t. or i.c.v. injection. The method of Hylden and Wilcox (1980) was used to inject 5 l of solution i.t. between L 5 and L 6 of the spinal cord with a 30-gauge needle. Intracerebroventricular injections were performed as described earlier (Pedigo et al., 1975) . Mice were anesthetized with 2.5% isoflurane, and a transverse incision was made in the scalp. A free-hand 5-l injection of drug was made into the lateral ventricle. Mice were tested as described above in the activity chambers 5 to 15 min after the injection. Antinociception, body temperature, and catalepsy were quantitated 20, 20, and 40 min, respectively, after the injection. All studies were carried out in accordance with the Declaration of Helsinki and Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health.
Data Analysis. Based on data obtained from numerous previous in vivo studies with cannabinoids, maximal cannabinoid effects in each in vivo pharmacological procedure were estimated as follows: 90% inhibition of spontaneous activity, 100% MPE in the tail-flick procedure, and Ϫ6°C change in rectal temperature. Means Ϯ S.E. were calculated for %MPE, number of photocell disruptions, % ring immobility, and ⌬°C. Analysis of variance was used to determine significant differences between control and treatment groups followed by Dunnett's t test post-hoc analysis. Statistical analysis was performed using StatView, version 5.0 (SAS Institute, Cary, NC). Significance was defined as a p Ͻ 0.05. ED 50 values were defined as the dose at which half-maximal effect occurred. For drugs that produced one or more cannabinoid effect, ED 50 values were calculated separately using least-squares linear regression on the linear part of the dose-effect curve for each measure in the mouse tetrad, plotted against log 10 transformation of the dose. For the purposes of potency comparison, potencies are expressed as micromoles/kilogram.
Synthesis of Compounds. All compounds were synthesized from various intermediates (2a-c) prepared using our published procedure (Singer et al., 1998) , starting with the commercially available 5-cyano-dimethoxyresorcinol 1 (Scheme 1). Compounds listed in Table 1 were synthesized from the acid 2c using standard procedures for the preparation of amides. The reverse amides (O-2589, O-2590, O-2619, and O-2620) were synthesized from 2a by conversion to the amine via the azide followed by condensation with the appropriate acids using either the acid chloride or the carbodiimide (EDCI/ DMAP) procedures. All of the N-alkylated compounds listed in Table  2 were synthesized from 2a by protection of the phenol as the t-butyl dimethylsiloxy derivative, which was treated with the appropriate amine in the presence of NaH/N,N-dimethylformamide, to give the target compounds. The C-alkylated imidazole derivative O-2737 was synthesized from 2c by conversion of the acid group to the aldehyde followed by condensation with glyoxal/NH 3 to form the 2-imidazole derivative (Dhanak et al., 2001) . The phenolic esters listed in Table  3 were synthesized from 2b using our published procedure (Razdan et al., 1976) . The various acids used in their preparation were prepared according to previously published procedures (Blicke et al., 1941; Cruickshank and Sheehan, 1961; Razdan et al., 1976) . The quaternary compounds were synthesized by the treatment of the amines with CH 3 I in ether. The compound listed in Table 4 was synthesized from the amide O-2372 (see Table 1 ) and diisopropylaminobutyric acid. HCl using the EDCI/DMAP procedure and the free base thus obtained was converted to its hydrochloride. All compounds showed appropriate 1 H NMR profiles (Jeol Eclipse 300 MHZ; Jeol USA, Inc., Peabody, MA) and were characterized on the basis of their 1 H NMR profiles, thin layer chromatography, and elemental analyses.
cLogP Calculations. cLogP (logarithm of the partition coefficient between n-octanol and water) calculations were performed using ChemDraw Ultra (CambridgeSoft Corp., Cambridge, MA).
Plasma Stability. Assays were performed at 37°C using a substrate concentration of 3 M in plasma (Wistar rat; Harlan Sera-Lab Ltd, Loughborough, UK; human; Biochemed Pharmacologicals Inc., Winchester, VA) or 0.5 M Tris buffer, pH 7.4. Samples (50 l) were Scheme 1. Structures of analogs. taken at 0, 10, 30, 60, and 150 min and were added to 150 l of acetonitrile containing internal standard (500 ng/ml desipramine). After centrifugation at 4°C, supernatant was transferred and was made 50% (v/v) aqueous with the addition of water. Analysis was performed by liquid chromatography-MS/MS (Micromass Ultima triple quadrupole mass spectrophotometer with multiplexing interface).
Microsomal Stability. Human hepatic microsomes were commercially obtained (BD Gentest; BD Biosciences, San Jose, CA). ICR mouse liver microsomes were prepared in-house from male animals fasted overnight. Freshly thawed microsomes were diluted to yield a final P450 concentration of 250 pmol/ml. The final concentration of test compound in the incubation was 1 M [with 1.25% acetonitrile (v/v), 0.25% DMSO (v/v)]. The microsomal mixture was preincubated for 15 min in a shaking incubator at 37°C. NADPH (1 mM final concentration) was then added to initiate the reaction. Samples (50 l) were taken at 0, 10, 30, and 60 min and were terminated by adding to 150 l of acetonitrile containing internal standard (500 ng/ml desipramine). Water (100 l) was added to the samples to give 50:50 aqueous/methyl cyanide. Samples were centrifuged at 4°C with analysis by liquid chromatography-MS/MS as described for plasma stability. P450 Inhibition. Assays were performed using human cDNAexpressed enzymes (Supersomes; BD Gentest) with probe substrates that were metabolized to strongly fluorescent compounds. Each P450-specific assay was performed using a substrate concentration at the apparent K m for that enzyme (as determined by BD Gentest). The following substrates and incubation times were used: CYP1A2, 7-ethoxy-3-cyanocoumarin (5 M), 15 min; CYP2C9, 7-methoxy-4-trifluoromethylcoumarin (75 M), 45 min; CYP2C19, 7-ethoxy-3-cyanocoumarin (25 M), 30 min; CYP2D6, 3-[2-(N,N-diethyl-Nmethylamino)ethyl]-7-methoxy-4-methylcoumarin (1.5 M), 30 min; and CYP3A4, 7-benzyloxyquinoline (40 M), 30 min. Incubations were performed according to the BD Gentest protocol using eight different final concentrations of test compound in 3-fold dilutions from 75 to 0.03 M (stock solution of 3.75 mM in 50:50 acetonitrile/ H 2 O). For each set of serial dilutions, two incubations in the absence of test compound (100% metabolite formation) and two with quenching solution added before P450 addition (background fluorescence) were also performed. All incubations were performed at a final concentration of 1% acetonitrile together with an NADPH-regenerating system (0.4 U/ml Glc-6-P dehydrogenase plus NADP ϩ [1.3 mM, except CYP2D6 at 8. The assays were performed in white 96-well plates (Greiner; Stonehouse, Gloucestershire, UK), and the fluorescence was measured using a fluorescence plate reader (Victor; EG&G Wallac, Mil- 
Results
Carboxamido Pentyl Side Chain Analogs.
There is ample evidence that a wide range of structural alterations at the terminal carbon of a dimethypentyl chain in THC can be made without diminishing cannabinoid pharmacological activity. For example, the addition of a cyano moiety at this position greatly enhances CB 1 receptor affinity and pharmacological potency (Martin et al., 1999) . Therefore, a series of carboxamido derivatives were analyzed as shown in Table 1 (structures in left column of Scheme 2). Most of the analogs exhibited high affinity for both CB 1 and CB 2 receptors, were effective in stimulating GTP␥S binding, and produced in vivo cannabinoid effects. The unsubstituted carboxamido (O-2352) exhibited excellent CB 1 receptor affinity and even higher CB 2 receptor affinity. GTP␥S binding indicated that it was a potent and fully efficacious agonist. In the in vivo mouse model, it was slightly more potent than ⌬ 9 -THC. Moreover, its lipophilicity was 35-fold less than that of ⌬ 9 -THC. CB 1 receptor affinity, efficacy (GTP␥S binding) and pharmacological potency were retained with carboxamido substitutions containing methyl (O-2490), morpholine (O-2544), homopiperidine (O-2489), or pyrrolidine (O-2543), although there were several notable differences among these compounds. The CB 2 receptor selectivity was greatly diminished with all substitutions and was actually reversed with the morpholino and homopiperdino analogs. Interestingly, the homopiperidino (O-2489) and pyrrolidino (O-2543) analogs were 4-to 25-fold less potent in producing hypothermia and catalepsy than they were in producing hypoactivity and analgesia. In addition, O-2490 failed to produce maximal effects in hypothermia and catalepsy assays at a dose (1 mg/kg) that produced maximal 
This analog was evaluated as described in Table 3 . For the in vivo studies, the drug was dissolved in saline. The ED 50 values are provided as micromoles/kilogram for reducing spontaneous activity (S.A.), producing antinociception in the tail-flick procedure (T.F), lowering rectal temperature (R.T.), and producing relative immobility (R.I.) after i.v. administration in mice. Solubility was determined by dissolving 1 mg of this analog in 1 ml of water. (O-2399) , and homopiperidino (O-2421) compounds having high CB 1 and CB 2 receptor affinity, high efficacy in GTP␥S binding, and very high in vivo potency in all four pharmacological measures. The most active compounds (O-2372 and O-2373) were 100 to 200 times more potent than ⌬ 9 -THC. It is noteworthy that replacement of a piperidine (O-2373) with a basic Nmethyl piperazine group (O-2381) decreased CB 1 receptor affinity and pharmacological potency more than 100-fold. Most of these compounds were slightly less lipophilic than ⌬ 9 -THC. Of the remaining compounds in Table 1 , only O-2619 demonstrated reasonable affinity for the CB 1 receptor; however, it was not evaluated in vivo.
Compounds O-2352, O-2372, O-2373, O-2399, and O-2544 were converted to hydrochloride salts as confirmed by NMR. However, none of the HCl salts was water-soluble. These analogs were deemed representative of the analogs in Table  1 , and therefore, no attempts were made to convert the other analogs in this table to HCl salts. Due to lack of water solubility, all of the analogs in Table 1 were administered to mice using the 1:1:18 Emulphor/ethanol/water vehicle. 
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Imidazole-, Pyrazole-, and Triazole-Pentyl Side Chain Analogs. The imidazole substitution (O-2545) on the terminal carbon atom of the side chain resulted in a highaffinity CB 1 agonist that was fully efficacious in stimulating GTP␥S binding (Table 2) . It exhibited even higher affinity for the CB 2 receptor. The free base of this analog, dissolved in 1:1:18 Emulphor/ethanol/water vehicle, produced the full spectrum of pharmacological effects in the mouse model and proved to be at least 40-fold more potent than ⌬ 9 -THC in all measures. The hydrochloride salt of O-2545 was dissolved in saline and, when administered to mice, produced effects that were equivalent to those of the free base. The calculated lipophilicity (cLogP) of this analog was 20 times less than that of ⌬ 9 -THC. A single methyl substitution at the 2 position of the imidazole (O-2651) reduced affinity for both CB 1 and CB 2 receptors: however, it was still water-soluble. This relatively minor structural alteration had a greater impact on efficacy in that it was only a partial CB 1 receptor agonist in GTP␥S binding. When administered in saline to mice, it was at least 10-fold less potent than the corresponding hydrochloride salt of O-2545. Both pyrazole (O-2715) and triazole (O-2716) analogs had high CB 1 receptor affinity and were fully efficacious in stimulating GTP␥S binding. They were also very potent in producing cannabinoid effects in the tetrad model. However, neither hydrochloride salts of these analogs was water-soluble. Merely changing the attachment position from the nitrogen on the imidazole (O-2545) to the carbon 2 position on the imidazole ring (O-2737) dramatically reduced CB 1 and CB 2 receptor affinities. As expected based upon their CB 1 receptor affinity, they exhibited only weak in vivo pharmacological activity.
Phenolic Esters. The phenolic esters in Table 3 represent an extension of earlier work on the morpholinobutyryloxy derivative of ⌬ 8 -THC (O-1057). As with O-1057, most of these analogs were water-soluble upon conversion to hydrochloride salts. Substituting the morpholino with a piperidino (O-2365) or methypiperidino groups (O-2426) slightly increased CB 1 receptor affinity over that of O-1057. Both analogs were effective in stimulating GTP␥S binding and very potently in the mouse behavioral assays. A methyl group was added to the carbon 1 position in the butyryl moiety in an attempt to delay hydrolysis and thereby increase duration of action. This addition produced only a slight reduction in CB 1 receptor affinity and pharmacological potency. The greatest difference was seen with lipophilicity, which was increased almost 100-fold by the addition of the methyl group to O-2365 but not to O-2426 O- . The N-4Ј-methylpiperazino analogs (O-2383 O- and O-2427 exhibited properties similar to the piperidino (O-2365) and 2-methyl-N-piperidino (O-2374) analogs. A series of N-alkylaminobutyryloxy analogs (O-2484, O-2487, O-2548, O-2650, O-2382, and O-2485) was prepared. For the most part, all of these analogs had good CB 1 receptor affinity, activated GTP␥S binding, and were potent when administered to mice (Table 3) . The 2-methyl analogs (O-2650 and O-2485) were somewhat less potent pharmacologically and had lower CB 1 receptor affinity. It is particularly noteworthy that the quaternary analog O-2548 is very potent pharmacologically. Of course, it also has high lipophilicity despite being a quaternary compound.
4-Diisopropylaminobutyrate of ⌬ 8 -THC-3-(1,1-Dimethyl-6-morpholin-4-yl-6-oxo-hexyl. The fact that the diisopropylaminobutyrate of ⌬ 8 -THC (O-2382 in Table 3 ) had high-receptor affinity and was extremely potent in vivo provided an opportunity to convert one of the water-insoluble carboxamido analogs in Table 1 to a water-soluble cannabinoid. Therefore, the morpholinocarboxamido (O-2372) was chosen, because it also has high-receptor affinity and excellent in vivo potency, despite being water-insoluble. The resulting analog, O-2694, was found to be water-soluble, retained high CB1 and CB2 receptor affinity, and exhibited high potency and efficacy in GTP␥S binding (Table 4) . It was also highly potent in vivo despite an almost 200-fold increase in lipophilicity compared with O-2372. However, according to cLogP values, it is only 5-fold less lipophilic than O-2382. Influence of Route of Administration. The absorption of ⌬ 9 -THC following oral administration is both poor and erratic. It is assumed that the high lipophilicity of ⌬ 9 -THC contributes to some extent to its low absorption. Therefore, the time course of three analogs with varying cLogP values was examined following their oral administration in mice (data not shown). O-2545 (24 times less lipophilic than ⌬ 9 -THC) was administered at a dose of 10 mg/kg, and different groups of mice were tested at 0.5, 1, 2, 4, and 6 h. The time course was similar for all four behavioral measures. For example, maximal analgesia in the tail-flick procedure was obtained at 30 min and remained at 85 Ϯ 11% (mean Ϯ S.E.M.) at 2 h. By 5 h, the effects had largely dissipated. O-2716 was 15-fold less lipophilic than ⌬ 9 -THC. Its oral administration at a dose of 10 mg/kg resulted in a time course very similar to that of O-2545. Maximal effects were observed at 30 min, and only a slight decrease in activity was observed at 2 h. At 4 h, few differences were observed between vehicleand O-2716-treated mice. The lipophilicities of O-2715 and ⌬ 9 -THC were almost identical. As predicted, the oral administration of O-2715 (10 mg/kg) produced negligible effects at 1 h (21 Ϯ 6% analgesia), and the effects declined over time.
Selected analogs as hydrochloride salts were also evaluated by direct injection into either the brain or spinal cord using saline as the vehicle (Table 5 ). These analogs were chosen as representatives of both phenolic esters (O-1057 and O-2383) and pentyl side chain analogs (O-2545, O-2737, and O-2651) . The reference compound ⌬ 9 -THC, prepared in the standard vehicle (combination of Emulphor, ethanol, and saline), was effective in all four behavioral measures, albeit with relatively weak potency. Whereas several general observations emerge, it is most noteworthy that all of the analogs were active when administered either i.c.v. or i.t. As expected, the analogs were more effective in suppressing spontaneous activity when given i.c.v. than i.t. In addition, the potencies of the analogs after being administered i.c.v. or i.t. were reflective of their potencies following i.v. administration. O-1057, O-2383, and O-2545 were more potent than O-2651 and O-2737, regardless of the route of administration. It is worthy to note that the side chain imidazole analog O-2737 was not active when administered i.v. at doses up to 10 mol/mouse but was as potent as ⌬ 9 -THC when injected either i.c.v. or i.t.
Inhibition of Cytochromes P450. As can be observed in Table 6 , several analogs were selected for metabolic studies because of their structural diversity. CP 55,940, O-1057, and O-581, the hydrolyzed form of O-1057, served as a comparison group. All three compounds exhibited little inhibitory effects on CYP1A2. However, they inhibited the other P450s more or less in the same concentration range. In comparison with O-1057, O-581 was 5-fold more effective in blocking CYP2C9 and 5-fold less effective in blocking CYP2D6. O-2545 differed from the above compounds in that it blocked CYP1A2 at 2 M and was much more effective than the comparison compounds in blocking CYP3A4. The inhibitory profile of O-2715 was quite similar to that of O-581. The primary difference between O-2715 and O-27l6 was the latter's increased potency at blocking CYP1A2.
Plasma and Microsomal Stability. All of the compounds that contain the ester group were rapidly metabolized in the rodent plasma with t 1/2 Ͻ 5 min ( Table 7) . The piperidinecontaining compound (O-2374) was also rapidly metabolized in human plasma. The other compounds were all stable in human plasma. The control incubations (buffer only) showed that there was some degradation of the compounds during the 37°C incubation, possibly by thermal decomposition (especially O-2548 and O-2487) . This is in contrast to the stability in human plasma, indicating that human plasma may act to protect the compounds, perhaps by protein binding. The ester-containing compounds were all rapidly metabolized when incubated with both mouse and human liver microsomes (Table 7) . For example, O-2548 was the most stable analog in mouse liver microsomes with a t 1/2 of 12 min. Most of these compounds have an element of non-P450-mediated metabolism (i.e., turnover in the absence of NADPH), perhaps because of microsomal esterase activity. Although O-2545 was a more stable compound than the other analogs examined, it was still metabolized reasonably quickly in microsomes from both species (t 1/2 ϳ10 min in both human and mouse liver microsomes).
Discussion
Extensive structure-activity relationship studies began almost immediately after the structure of ⌬ 9 -THC was established (Gaoni and Mechoulam, 1964; Edery et al., 1971; Razdan, 1986) . These initial studies firmly established the importance of three structural features of ⌬ 9 -THC: the C9 position, phenolic hydroxyl group, and pentyl side chain. These regions of the molecule continue to be the focus of structural modifications of THC. Elimination or structural modification of the phenolic hydroxyl group rendered THC inactive at the CB 1 receptor (Razdan, 1986) . Recently, a series of desoxy-⌬ 8 -THC analogs were found to lack CB 1 receptor affinity but retained their ability to interact with CB 2 receptors (Huffman et al., 2002) . The side chain can easily be manipulated to increase agonist potency or to reduce or eliminate agonist efficacy (Martin et al., 1999) . In addition, the terminal carbon atom of the side chain can Water-Soluble Cannabinoids metabolic activation, these compounds are active when injected directly into brain or spinal cord. In addition, incorporation of nitrogen-containing rings at the terminal carbon atom of the side chain allows for the preparation of hydrochloride salts that are readily water-soluble. The advantage of these compounds is that they do not require metabolic activation. It is now possible to use these same synthetic strategies to develop water-soluble CB 1 -and CB 2 -selective agonist and antagonists. The necessity of using solubilizing agents to evaluate the pharmacological properties of an agent poses challenges to the investigator. There is always the possibility of a pharmacological interaction between vehicle and test agent. More likely, the vehicle will influence the pharmacokinetics of the test substance that adds an additional challenge when comparing data generated from different laboratories that use various vehicles. Elimination of solubilizing agents as a vehicle removes possible artifacts arising from these substances. Incorporation of nitrogen-containing rings at the terminal carbon atom of the THC side chain allows for the first time the synthesis of CB 1 receptor agonists that do not require metabolic conversion in order to be water-soluble.
